Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;107(6):100041.
doi: 10.1016/j.molpha.2025.100041. Epub 2025 Apr 21.

Isoprenaline shows unique kinase dependencies in stimulating β1AR-β-arrestin2 interaction compared to endogenous catecholamines

Affiliations

Isoprenaline shows unique kinase dependencies in stimulating β1AR-β-arrestin2 interaction compared to endogenous catecholamines

Edda S F Matthees et al. Mol Pharmacol. 2025 Jun.

Abstract

The β1-adrenergic receptor (β1AR) is an essential G protein-coupled receptor in the heart. Its dysregulation represents a hallmark of cardiac diseases. Studies have identified a unique mode of β-arrestin interaction, where β1AR briefly engages with β-arrestins before catalytically accumulating them at the plasma membrane (PM) independently of the receptor. Although receptor phosphorylation crucially impacts β-arrestins, the contributions of specific kinases vital in β1AR regulation remain unclear. Here, we employed G protein-coupled receptor kinase (GRK) GRK2/3/5/6 knockout cells and the protein kinase A inhibitor H89 in bioluminescence resonance energy transfer-based assays to systematically assess GRKs and protein kinase A in direct β-arrestin2 recruitment to β1AR and β-arrestin2 translocation to the PM. Furthermore, we compared the effects of the synthetic agonist isoprenaline with the endogenous catecholamines: epinephrine and norepinephrine. We observed pronounced differences in their kinase dependencies to mediate β-arrestin2 translocation to the PM. Upon isoprenaline stimulation, GRKs strongly influenced β-arrestin2 translocation to the PM but had no effect on direct β-arrestin2 recruitment to β1AR. Additionally, in a GRK2-specific context, protein kinase A inhibition primarily reduced the efficacy of isoprenaline for β-arrestin2 translocation, whereas for GRK5, it decreased potency. Strikingly, these kinase-dependent effects were absent for epinephrine and norepinephrine, suggesting distinct underlying molecular mechanisms for β-arrestin2 accumulation at the PM. This observation could be explained by agonist-specific differences in receptor conformational rearrangements, as suggested by distinct changes in the NMR spectra of β1AR. Our findings highlight that synthetic and endogenous ligands induce distinct molecular mechanisms in β1AR regulation, emphasizing the need to consider these differences when translating molecular insights into physiological contexts. SIGNIFICANCE STATEMENT: Our findings reveal mechanistic differences in β1-adrenergic receptor-mediated catalytic activation of β-arrestin2 by synthetic and endogenous agonists, driven by distinct G protein-coupled receptor kinases and protein kinase A dependencies. Although β-arrestin2 translocation to the PM occurred to similar extents with isoprenaline, epinephrine, and norepinephrine, kinase involvement was crucial only upon Iso stimulation of β1-adrenergic receptor. By elucidating these ligand-specific pathways, this study advances our understanding of β1-adrenergic receptor signaling and regulation while additionally highlighting the importance of considering these differences when translating molecular insights into pathophysiological contexts.

Keywords: Bioluminescence resonance energy transfer; G protein-coupled receptor kinases; G protein-coupled receptors; Nuclear magnetic resonance spectroscopy; Protein kinase A; β-arrestin2 translocation.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest Carsten Hoffmann reports financial support was provided by European Regional Development Fund. Alvar D. Gossert reports financial support was provided by Swiss National Science Foundation. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Iso-mediated β-arrestin2 interaction with the β1AR. (A) Schematic representation of the direct β-arrestin2 recruitment NanoBRET assay (PDBs: β1AR, 7BTS; β-arrestin2, 3P2D; β1AR–β-arrestin complex, 6TKO; NanoLuc, 7MJB; HaloTag, 8SW8). (B) Concentration–response curves of direct β-arrestin2 recruitment to β1AR, normalized to the maximum signal in Control cells. Control and ΔQ-GRK (GRK2/3/5/6 knockout) cells were transfected with β1AR-NanoLuc and HaloTag-β-arrestin2 and stimulated with the indicated concentration of Iso. (C) Schematic depiction of the assay measuring β-arrestin2 translocation to the PM (PDBs: β1AR, 7BTS; β-arrestin2, 3P2D, 5TV1; NanoLuc, 7MJB; and YFP, 4NDK). (D) Concentration–response curves of β-arrestin2 translocation to the PM, upon β1AR stimulation, normalized to the maximum signal in Control cells. Control and ΔQ-GRK cells were transfected with unlabeled β1AR, β-arrestin2-NanoLuc, and YFP-CAAX and stimulated with the indicated concentration of Iso. All measurements are shown as the mean of at least n = 3 independent experiments ± SEM. Statistical analysis was performed using an unpaired two-tailed t test (ns, not significant; ∗∗∗∗, P < .0001), detailed results can be accessed in Supplemental Table 1. (E, F) Representative confocal microscopy images of Control and ΔQ-GRK cells, transfected with β1AR-CFP, β-arrestin2-YFP, and Rab5-mCherry, before and after stimulation with 1 μM Iso for 15 min.
Fig. 2
Fig. 2
Effect of PKA on GRK-specific β-arrestin2 interaction with the β1AR. (A–D) Concentration–response curves of direct β-arrestin2 recruitment to β1AR under endogenous GRK expression (A), in ΔQ-GRK cells without GRKs present (B) and with overexpression of GRK2 (C) or GRK5 (D) in ΔQ-GRK cells. All assays were performed in the absence and presence of 5 μM PKA inhibitor H89, after 30 minutes of incubation at 37 °C with 10 μM H89. (E–H) Concentration–response curves of β-arrestin2 translocation to the PM, upon β1AR stimulation in the same conditions as for the direct β-arrestin2 recruitment (A–D). All curves were normalized to the maximum response measured in Control cells upon Iso stimulation in the respective assays (A, E) and data points are displayed as mean of at least n = 3 independent experiments ± SEM. Statistical analysis was performed using a two-way ANOVA, followed by a Sidak test to compare values at maximal stimulation in the absence and presence of H89 (∗, P < .05). Detailed results can be accessed in Supplemental Table 3, additionally for comparisons of each condition with measurements in Control cells in absence of H89 (two-way ANOVA, followed by a Dunnett’s test). Data for Control and ΔQ-GRK cells in the absence of H89 (A, B, E, F) are shown again from Fig. 1 to allow a direct comparison of the effect of PKA inhibition.
Fig. 3
Fig. 3
Effect of PKA on GRK-specific Epi- and NE-mediated β-arrestin2 translocation to the PM. (A–H) Concentration–response curves of β-arrestin2 translocation to the PM upon β1AR stimulation with the endogenous agonist’s Epi (A–D) or NE (E–H). Transfections and assays were performed as described. All curves were normalized to the maximum response measured in Control cells upon Iso stimulation (Fig. 2E) and data are shown as the mean of at least n=3 independent experiments ± SEM. Statistical analysis was performed using a two-way ANOVA, followed by a Sidak test to compare values at maximal stimulation in the absence and presence of H89 or followed by a Dunnett’s test to compare each condition with measurements in Control cells in the absence of H89. All results can be accessed in Supplemental Table 4.
Fig. 4
Fig. 4
Direct comparison of ligand-specific cAMP response using the EPAC1-cAMPs sensor. (A) Schematic representation of the used EPAC1-cAMPs sensor [PDBs: YFP, 4NDK; CFP, 3ZTF; part of EPAC1 used for sensor (E157–E316), 6H7E] (Nikolaev et al, 2004). (B) Changes in the baseline- and vehicle-normalized FRET ratio over time upon stimulation of β1AR. Control cells featuring endogenous kinase expression were transfected with β1AR and the EPAC-cAMPs sensor and measured over 30 min after the addition of the indicated ligand (1 μM Iso, 30 μM Epi, or 30 μM NE). (C) Values between approximately 45 and 90 s after stimulation were averaged and displayed as a bar graph. All data are shown as n = 3 independent experiments ± SEM. Statistical analysis was performed using a one-way ANOVA, followed by a Tukey test (ns, not significant). Detailed results can be accessed in Supplemental Table 5.
Fig. 5
Fig. 5
Ligand-specific NMR spectra of 13Cε-Met-labeled β1AR. (A) AlphaFold2 (Jumper et al, 2021) model of the used β1AR construct. Methyl groups of the methionine residues are marked as purple spheres. The orthosteric binding site is indicated via Epi (shown as blue spheres) through an alignment with Epi-bound β1AR (PDB: 7BTS). Additionally, the chemical structures of the ligands used in this direct comparison are shown. (B–D) 2D [13C, 1H] NMR correlation spectra of 13Cε-Met-labeled β1AR in the apo state (B, gray) or in the presence of Iso (B–D, orange), Epi (C, blue) or NE (D, green). Distinct chemical shifts are marked with black boxes (C, D).

References

    1. Belmonte S.L., Blaxall B.C. G protein coupled receptor kinases as therapeutic targets in cardiovascular disease. Circ Res. 2011;109:309–319. - PMC - PubMed
    1. Benovic J.L., Kühn H., Weyand I., Codina J., Caron M.G., Lefkowitz R.J. Functional desensitization of the isolated beta-adrenergic receptor by the beta-adrenergic receptor kinase: potential role of an analog of the retinal protein arrestin (48-kDa protein) Proc Natl Acad Sci U S A. 1987;84:8879–8882. - PMC - PubMed
    1. Boucrot E., Ferreira A.P., Almeida-Souza L., Debard S., Vallis Y., Howard G., Bertot L., Sauvonnet N., McMahon H.T. Endophilin marks and controls a clathrin-independent endocytic pathway. Nature. 2015;517:460–465. - PubMed
    1. Bristow M.R., Ginsburg R., Umans V., Fowler M., Minobe W., Rasmussen R., Zera P., Menlove R., Shah P., Jamieson S., et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986;59:297–309. - PubMed
    1. Brodde O.E. Beta-adrenoceptors in cardiac disease. Pharmacol Ther. 1993;60:405–430. - PubMed

MeSH terms

LinkOut - more resources